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Human herpesvirus 6 variants A and B (HHV-6A and HHV-6B, respectively) encode homologs (U94) of the parvovirus
nonstructural gene, ns1 or rep. Here we describe the HHV-6B homolog and analyze its genetic heterogeneity and
transcription. U94 nucleotide and amino acid sequences differ by approximately 3.5% and 2.5%, respectively, between
HHV-6A and HHV-6B. Among a collection of 17 clinically and geographically disparate HHV-6 isolates, intravariant nucleotide
and amino acid sequence divergence was less than 0.6% and 0.2%, respectively; all 13 HHV-6B isolates had identical amino
acid sequences. The U94 transcript is spliced to remove a 2.6-kb intron and is expressed at very low levels relative to other
HHV-6B genes, reaching approximately 10 copies per cell 3 days after infection. The mRNA has several small AUG-initiated
open reading frames upstream of the U94 open reading frame, a hallmark of proteins expressed at low levels. Consistent with
this, the U94-encoded protein was immunologically undetectable in HHV-6B-infected cells. The high degree of sequence
conservation suggests that the gene function is nearly intolerant of sequence variation. The low abundance of U94
transcripts and the presence of encoded inefficient translation initiation suggest that the U94 protein may be required only
in small amounts during infection. © 2000 Academic Press
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Human herpesvirus 6 (HHV-6) isolates belong to one
of two closely related, yet distinct, variants: HHV-6A and
HHV-6B (Ablashi et al., 1991, 1993; Schirmer et al., 1991).
Variant A has not been etiologically associated with any
disease (reviewed in Braun et al., 1997). Variant B is the
etiological agent of exanthem subitum (roseola) and
other febrile illnesses in children (Pruksananonda et al.,
1992).
HHV-6A and HHV-6B encode several polypeptides
with no known counterparts in other herpesviruses. One
example is U94, a homolog of the parvovirus replication
gene ns1 (or rep) gene, which was first identified for
HHV-6A (Thomson et al., 1991). HHV-6A U94 has 24%
amino acid identity to the amino-terminal 490 amino
acids of the adeno-associated virus type 2 (AAV-2) Rep
68/78 protein. In a comparison between the genomic
sequences of HHV-6A and HHV-6B (Dominguez et al.,
1999), we found that the genomes are most divergent in
the direct repeats (DR) that bound the unique segment
(Fig. 1) and across the 30 kb of sequence at the right end
of the unique segment that encodes open reading
frames U86-U100. In this region, each open reading
frame has less than 90% amino acid identity between the
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504variants, except for U94 (97.6% identity). Nucleotide se-
quences of HHV-6 isolates are highly conserved, with
intravariant heterogeneity seldom exceeding 0.5% (typi-
cally 0.1%) and intervariant heterogeneity from gene to
gene ranging from less than 2% to 24% (typically 5%)
(Dominguez et al., 1999, and reviewed in Braun et al.,
1997).
AAV-2 Rep68/78 (RepAAV-2) is a multifunctional protein
essential for AAV-2 DNA replication (reviewed in Berns,
1996; Berns and Giraud, 1996). It is involved in regulation
of AAV-2 gene expression and site-specific integration of
the AAV-2 provirus into human chromosome 19 (Chiorini
et al., 1996; Linden et al., 1996; Surosky et al., 1997).
RepAAV-2 can repress heterologous gene expression, in-
cluding the HIV-1 long terminal repeat promoter; sup-
press herpes simplex virus-induced SV40 DNA amplifi-
cation (Heilbronn et al., 1990); and prevent oncogenic
ransformation by transcriptional suppression of onco-
ene expression. Biochemical properties of RepAAV-2 in-
clude sequence-specific DNA binding to AAV-2 terminal
repeats (Ryan et al., 1996), AAV-2 promoter regions
(Pereira and Muzyczka, 1997a), and the human chromo-
some 19 integration site (Weitzman et al., 1994). In addi-
ion, it has strand- and sequence-specific endonuclease
ctivity and ATP-dependent helicase activity and inter-
cts with transcription factors (Hermonat et al., 1996;
ereira and Muzyczka, 1997b).The U94 protein shares some functions with AAV-2
ep 68/78. Ectopically expressed HHV-6A U94 comple-
505HHV-6B U94 SEQUENCE AND EXPRESSIONFIG. 1. HHV-6B genes and genomic regions studied in this work. Regions corresponding to the HHV-6A repeat arrays R1, R2, and R3, the left and
right terminal direct repeats (DRL and DRR), and the origin of replication are shown. The structure of the spliced transcript that spans U94 is
diagrammed below the enlarged U94 and U95 genes.FIG. 2. Nucleotide and amino acid heterogeneity between U94 of HHV-6 isolates. (A) Nucleotide and amino acid differences among HHV-6B
isolates. The corresponding sequence of the HHV-6A isolates is shown for reference. (B) Nucleotide and amino acid differences among HHV-6A
isolates. The corresponding sequence of the HHV-6B isolates is shown for reference. Although in this representation, HHV-6A group 2 appears to
be very closely related to HHV-6B, the complete intervariant comparison shown in Fig. 3 clearly indicates otherwise. For each section, the upper table
describes nucleotide positions at which isolates differed and any corresponding amino acid changes. The lower lines are scaled graphic
representations of the distribution of nucleotide and amino acid differences. The letters and number following the HHV-6A or HHV-6B designation
indicate the origin of each isolate as described in Materials and Methods.
a
t
t
h
p
U
c
d
c
a
U
H
i
r nces.
d
506 RAPP ET AL.ments DNA replication of Rep-deficient AAV-2 (Thomson
et al., 1994), regulates gene expression in cotransfection
ssays (Araujo et al., 1995), and can prevent oncogenic
ransformation, possibly through a mechanism involving
ranscriptional regulation (Araujo et al., 1997). Thus U94
as retained some of the biochemical activities of its
arvovirus counterpart. Recently, transcripts spanning
94 were identified by reverse transcription–polymerase
hain reaction (RT-PCR) as the only HHV-6B transcripts
etected in latently infected peripheral blood mononu-
lear cells obtained from healthy adult donors (Rotola et
l., 1998). In addition, cell lines containing the HHV-6B
94 gene were refractory to productive infection by
HV-6A (Rotola et al., 1998).
In this report, we describe genetic relationships in U94
among 17 HHV-6A and HHV-6B isolates, detected the
U94 transcript in HHV-6B-infected cells by RT-PCR, and
mapped its termini. To characterize the transcriptional
regulation of the gene, the absolute amount of its tran-
script was compared with those of HHV-6B genes pre-
dicted to belong to various kinetic classes. The expres-
FIG. 3. Nucleotide and amino acid differences between HHV-6B an
solates differed and any corresponding amino acid changes; unique
epresentations of the distribution of nucleotide and amino acid differe
escribed in Figure 2.sion of these same genes was examined in the absence
of de novo protein synthesis.RESULTS
Genetic heterogeneity of U94 among HHV-6 clinical
isolates
As a guide for future functional studies, genetic heter-
ogeneity among U94 sequences was analyzed to assess
global sequence variation in the gene and to identify
regions that might be critical for U94 biochemical func-
tion. The U94 nucleotide sequence was determined from
12 low-passage HHV-6B clinical isolates and compared
with that of HHV-6B(Z29) (Fig. 2A). The nucleotide se-
quences of all of the HHV-6B clinical isolates except J1-L
belonged to one of three groups that differed at most by
four nucleotides in pairwise comparisons. U94 of the 12
HHV-6B clinical isolates each had greater than 99.7%
nucleotide and 100% amino acid identity with HHV-
6B(Z29) U94. The nucleotide at position 750 of HHV-6B
J1-L appears to be a mixture of C and T. Although not
included in our analysis, the recently published HHV-
6B(HST) U94 sequence (Isegawa et al., 1999) differs from
HHV-6B(Z29) at four nucleotide positions, with no amino
6A isolates. The upper table describes nucleotide positions at which
tides and amino acids are bold. The lower lines are scaled graphic
The group numbers following the HHV-6A or HHV-6B designation ared HHV-
nucleoacid differences.
The U94 nucleotide sequences from three HHV-6A
507HHV-6B U94 SEQUENCE AND EXPRESSIONisolates from Cologne (Germany) were identical, differing
from HHV-6A(U1102) by nine nucleotides (99.4% identity),
with one resulting conservative amino acid difference
(99.8% identity) (Fig. 2B). At seven of the nine positions
where the HHV-6A isolates varied, the nucleotide was
the same among the German HHV-6A isolates and all of
the HHV-6B isolates.
As expected, there were considerably more nucleotide
and amino acid differences in pairwise intervariant com-
parisons than in intravariant comparisons (Fig. 3). The 17
U94 sequences clearly partitioned into two variant-specific
categories. In addition, within each variant, there was fur-
ther segregation that corresponded to the geographical
origin of the isolates, although the number of isolates stud-
ied and the high conservation preclude firm conclusions.
All HHV-6A isolates have a V-to-M substitution at
amino acid 26. This sequence difference leads to a third
possible translational start in HHV-6A U94 mRNA, GC-
CCCAUGG, that more closely corresponds to the Kozak
consensus sequence (Kozak, 1989, 1991) for efficient
translation initiation than two upstream AUG codon en-
vironments in this ORF. However, as shown later, we
found no evidence in an in vitro translation system that
this initiation codon is used.
U94 mRNA expression in HHV-6B(Z29)-infected cells
U94 expression was not detected in HHV-6B(Z29)-
infected lymphocytes by either Northern blotting (G.
Dominguez and P.E.P., unpublished data) or by immuno-
blotting or immunofluorescence assays with anti-peptide
antibodies reactive with U94 protein expressed in recom-
binant baculovirus-infected insect cells (data not shown).
In addition, of 60 human serum specimens tested, none
had detectable antibodies to U94 in an immunoblot as-
say that used baculovirus-expressed U94 as antigen
(data not shown). Because of the apparent low-level
expression of U94, we assayed its transcription by RT-
PCR. U94-specific amplification by RT-PCR was obtained
only from mRNA isolated from HHV-6B(Z29)-infected
cells (Fig. 4, lane 8). Hybridization of DNA from the
reactions shown in Fig. 4 with a radiolabeled oligonucle-
otide (U94 probe, Table 1) confirmed the specificity of the
amplification (data not shown). Similar results were ob-
tained with mRNA isolated from HHV-6B(Z29)-infected
umbilical CBLs (data not shown).
U94 transcript mapping
To verify that the mRNA detected above originated as
U94 transcripts and to define the boundaries of the
transcripts for the purpose of identifying regulatory ele-
ments, the 59 termini were mapped by RNA ligase-me-
diated rapid amplification of cDNA ends (RLM-RACE).
The nucleotide sequence of the largest DNA band (rep-
resenting the farthest upstream U94 59 terminus de-
tected) indicated that the U94 transcript is spliced, the d2.6-kb intron extending from nucleotide positions
147512–144904. Of the 13 largest RLM-RACE amplimers
cloned and sequenced, nine mapped to a single site
(nucleotide position 147567) at an appropriate distance
(25 nucleotides) downstream from a possible TATA box
(Fig. 5). To confirm the existence of the U94 splice site,
primers bracketing the splice site (primers 122 and 124,
Table 1) were used for either PCR amplification of HHV-
6B(Z29) nucleocapsid DNA or for RT-PCR of mRNA ex-
tracted from HHV-6B(Z29)-infected CBLs. The sizes of the
observed amplimers were in accordance with the pre-
dicted size of the intron (data not shown). Although we
did not experimentally assess their use, the splice sites
are present in the HHV-6A(U1102) sequence.
The U94 39 transcript terminus was mapped by RLM-
RACE (Liu and Gorovsky, 1993) instead of the standard
RACE technique because of a homopolymeric stretch of
adenylic acid residues located 45 bp downstream from
the U94 reading frame. A single polyadenylation site was
identified at nucleotide position 142891 (Fig. 5). The DNA
sequence surrounding the polyadenylation site contains
consensus features of mRNA 39 cleavage and polyade-
nylation signals (Fig. 5); notably, the sequence AATACA
was found instead of the canonical AATAAA polyadenyl-
ation signal. Using the 39 RLM-RACE technique, we
1
FIG. 4. RT-PCR detection of U94 transcripts. mRNA was extracted 3
days after HHV-6B(Z29) infection of Molt-3 cells. RT-PCR was con-
ducted as described in Materials and Methods for QC RT-PCR. Lanes
1 and 10 contain 100-bp DNA ladder molecular weight standards
(GIBCO BRL). Lane 2 contains the PCR product of a reaction using
human b-actin sequences as primers (Inoue et al., 1994) and mock-
infected Molt-3 cell cDNA as template. Lane 3 contains the PCR
product of a reaction using primers U94RTP5 and U94RTP3 (Table 1)
and a nucleocapsid preparation of HHV-6B(Z29) DNA as template.
Lanes 4–9 are RT-PCRs performed under the indicated conditions:
reverse transcriptase (RT); mock-infected (2), or HHV-6B(Z29)-infected
(1) Molt-3 cells.found products with poly(A) tails 6–10 residues long. We
o not know whether the U94 poly(A)1 tail lengths are
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508 RAPP ET AL.truly this short or if short poly(A)1 tails are preferentially
mplified by 39 RLM-RACE.
uantification of HHV-6B(Z29) mRNA levels during
ytic infection
U94 mRNA expression levels were determined both
bsolutely and relative to other HHV-6B(Z29) transcripts
y using quantitative-competitive (QC) RT-PCR. The ref-
rence transcripts studied were chosen because of their
redicted kinetic properties. U11 is predicted to be ex-
ressed as a late gene and encodes the 101-kDa virion
rotein (Pellett et al., 1993). U42 encodes a homolog of
he herpes simplex virus type 1 (HSV-1) a27 gene (Seku-
T
Oligonucleotid
Gene Primer
U11 U11out5 59-AGATGGA
U11out3 59-ACATCAC
U11mut 59-TAGAAAG
U11mutrc 59-GAGGATC
U11RTP5 59-AGCCGAA
U11RTP3 59-CGGAGAC
U42 U42out5 59-AAGCAAA
U42out3 59-ACGAGAA
U42mut 59-ACCTAAC
U42mutrc 59-TGTTTTTA
U42RTP5 59-CATGCAG
U42RTP3 59-ATCTGGT
U73 U73out5 59-GTGTCTA
U73out3 59-AATCGGT
U73mut 59-AGGCCTC
U73mutrc 59-CCGCCTT
U73RTP5 59-GTGACGG
U73RTP3 59-CAACTTC
U90 U90out5 59-TGGATTTT
U90out3 59-ACATCTA
U90mut 59-TAAACAC
U90mutrc 59-GTTTGGC
U90RTP5 59-GCAAAAC
U90RTP3 59-TTCGGCT
U94 U94out5 59-CACAAAC
U94out3 59-CAGGGTG
U94mut 59-ATGGAAT
U94mutrc 59-AGATCCG
U94RTP5 59-CTTTTGAC
U94RTP3 59-ATGTCTTT
U94probe 59-ATCCCGT
081 59-TTCTCGA
080 59-TTCTCGA
122 59-TTACTAGT
124 59-TTGGTAC
U94PCR5 59-TTCGTCA
U94PCR3 59-GTTGGAT
a Underlined nucleotides were altered to generate restriction sites e
erived nucleotides.
b Coordinates are from the HHV-6B(Z29) genome, GenBank accessilovich et al., 1988) and the HCMV UL69 gene (Winkler et
al., 1994); the HSV-1 counterpart is an a or immediate-arly (IE) gene, whereas HCMV UL69 is expressed as a
elayed-early gene (Winkler et al., 1994). U73 encodes
the origin binding protein and would be predicted to be
expressed as an early gene (Inoue et al., 1994). HHV-
6B(Z29) U90 corresponds to the HHV-6A IE gene U89
(Schiewe et al., 1994; Dominguez et al., 1999). The
genomic locations of these genes are shown in Fig. 1.
mRNA expression was initially studied for each of these
genes in a manner similar to that shown in Fig. 4 for U94
(Inoue et al., 1994, data not shown). In each case, the
oligonucleotide PCR primers in the RT-PCR amplified a
single band specific to HHV-6B(Z29)-infected cells.
Several items deserve mention before describing the
d in the Study
er sequencea Coordinatesb
AAGCGGCAG-39 22536–22517
GATCACTG-39 19955–19974
CTGCAGTTAGTGATCCTC-39 20391–20362
CTGCAGGAATTCTTTCTA-39 20362–20391
AAATCTGA-39 20519–20500
AGAATC-39 20306–20323
ATCCTCGT-39 71661–71642
TGACGACG-39 69839–69858
TAAAAACA-39 70353–70334
GTTAGGT-39 70334–70353
CAACAAGT-39 70467–70448
TTGTCGG-39 70280–70299
CTGGAGGC-39 109605–109624
GTAGATCT-39 112034–112015
CAAGGCGG-39 111858–111877
CGAGGCCT-39 111877–111858
TTTTCTAT-39 111638–111657
CGGAAAGG-39 111935–111916
TTGGTGC-39 137692–137673
CATCTAGC-39 134984–135003
AGCCAAAC-39 135448–135329
AGTGTTTA-39 135329–135448
TGGAAGAC-39 135436–135417
AAGATTTT-39 135231–135250
GTTTTCCA-39 144575–144556
TCAGCGTC-39 142995–143014
ACGGATCT-39 143493–143474
AATTCCAT-39 143474–143493
TATTAGCAGG-39 143637–143616
CACAAGAC-39 143415–143434
GGAATATTACACGGATCT-39 143503–143474
AAAAAAATCCGTAGAT-39 144442–144462
AAATCATCACTTGGA-39 144530–144548
AAAACCGCGAATCACT-39 144862–144881
GGAGAACCACCATG-39 147617–147600
GGACGAGATT-39 144738–144717
TTATAATGTGATGTC-39 143011–143029
or those in U90out3, which are underlined to indicate HHV-6A(U1102)-
ber AF157706.ABLE 1
es Use
Prim
TTTGA
GACGC
AATTC
ACTAA
TTTAC
TGCAC
CATGT
GGTTA
ATCGA
TCGAT
CTATT
ATTTTG
CACGA
ACTCT
GATAT
GATAT
GTGTG
ACTAA
TTTAA
GGTTT
TGCAG
TCTGC
AGACT
GTTAC
GGTAT
AGTTA
TCTAG
TCTAG
CCTA
CCAC
TACAT
GTGCA
GCCAA
GATC
CCACA
CACGT
CCGTC
xcept fQC RT-PCR results. (1) The competitive templates were
designed to resemble in length and content the mRNA
ylic ac
a
u
509HHV-6B U94 SEQUENCE AND EXPRESSIONspecies predicted from ORF lengths and sequences. (2)
The amplification method is limited in that it measures
only steady-state mRNA levels and is unable to distin-
guish the strandedness of transcription across the am-
plified locus. The latter is because random hexamer
primers were used at the cDNA synthesis step to ensure
that uniform pools of cDNAs were available for amplifi-
FIG. 5. U94 transcript mapping by RLM-RACE. (A) 59 RLM-RACE prod
the number of sequenced oligo-cap products that mapped to a parti
element. Coordinates for the splice site of the U94 transcript are
Polyadenylation site of the U94 transcript as determined by 39 RLM-RAC
above the sequence (Birnstiel et al., 1985). The bottom line of sequence
in length from 6 to 10 residues). The C that varies from the fourth aden
the G/T cluster is underlined.
FIG. 6. Time course of transcript accumulation and dependence on d
mRNA levels were measured by QC RT-PCR at various times after sy
transcript copy/cell (approximately 104 transcript copies/reaction). Tran
extraction and do not directly reflect the percent of cells infected. (B)
mRNAs. Molt-3 cells were treated with 50 mg/ml emetine before HHV-6t 0 and 8 h p.i., and transcript copy numbers were determined by QC RT-PCR
sed for RNA extraction and do not reflect percent infectivity.cation with the gene-specific primers. (3) The QC-RT PCR
experiment described in Fig. 6A describes events that
occurred in a single infected-cell culture. All of the as-
says at a particular time point were conducted using the
same preparation of mRNA. Results obtained with the
initial 10-fold and subsequent 2-fold dilution series were
internally consistent, as were independent repeat anal-
at mapped upstream of the splice site. Arrows with numbers indicate
ite. The underlined region indicates a potential “TATA box” promoter
d, and the corresponding HHV-6A(U1102) sequence is shown. (B)
sensus features of 39 cleavage and polyadenylation signals are shown
sents the 39 RLM-RACE products that contained poly(A)1 tails (ranging
id residue found in the canonical AATAAA element is highlighted, and
protein synthesis. (A) Transcript kinetics. U11, U42, U73, U90, and U94
ized infection of Molt-3 cells. The lower limit of quantitation was 0.01
opies/cell values are based on the total number of cells used for RNA
f protein synthesis inhibition on synthesis of U42, U73, U90, and U94
nfection as described in Materials and Methods. mRNA was extracteducts th
cular s
indicate
E. Con
repree novo
nchron
script c
Effect o
B(Z29) i. Transcript copies/cell values are based on the total number of cells
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510 RAPP ET AL.yses on several of the samples (data not shown). (4) The
results shown in Fig. 6A are consistent with independent
experiments that followed slightly different time courses
(data not shown).
As shown in Fig. 6A, mRNA levels for the HHV-6B(Z29)
genes studied varied by as much as two orders of mag-
nitude by 74 h postinfection (p.i.). U11, which encodes an
abundantly expressed structural gene, was expressed at
the highest levels in comparison to the other genes as
early as 26 h p.i., reaching approximately 600 copies per
cell by 74 h p.i. of Molt-3 cells. For U42, a putative HHV-6
transcriptional regulator, mRNA levels increased sharply
(approximately 10-fold) within the first 14 h of infection
and then remained at approximately 30 copies per cell
for the 14- to 74-h time course. U73 transcripts, which
encode a protein involved in DNA replication, were
among the least abundant. Levels of these transcripts
increased steadily to a maximum of approximately 20
copies per cell at 50 h p.i. and declined to less than 10
copies per cell by 74 h p.i. Typical of an IE gene, U90
mRNA levels increased rapidly to approximately 16 cop-
ies per cell during the first 8 h of infection, decreased
approximately 4-fold during the next 6 h, and then in-
creased during the remainder of the time course to reach
a maximal level of approximately 400 copies per cell by
74 h p.i. U94 mRNA levels remained below approximately
1 copy per cell until 50 h after infection, reaching a
maximum of approximately 10 copies per cell at 74 h after
infection. It should be noted that only mRNA levels were
measured by QC RT-PCR and not protein levels, although
in other experiments that used similar materials, immu-
noblots showed high levels of U11 protein (Pellett et al.,
1993), moderate levels of U42 and U90, and undetectable
levels of U73 and U94 (N.I., C. Ko, and P.E.P., unpublished
data).
Effect of protein synthesis inhibition on HHV-6B(Z29)
mRNA synthesis
We studied the dependence of U94 transcription on de
novo protein synthesis. As was done earlier for transcript
quantification, several genes expected to represent dif-
ferent kinetic classes were included as controls.
U90 transcripts accumulated to the same levels in
either the absence or presence of de novo protein syn-
thesis (Fig. 6B), extending to HHV-6B the results of
Schiewe et al. (1994), who reported that HHV-6A(U1102)
U89 is transcribed in the presence of cycloheximide. In
the presence of emetine, U42 transcripts did not accu-
mulate, indicating that U42 is not expressed as an IE
gene in Molt-3 cells. In contrast, HSV-1 a27 is expressed
as an IE gene (Sekulovich et al., 1988). The HCMV ho-
olog of this gene, UL69, is expressed as an early-late
ene (Winkler et al., 1994), suggesting that HHV-6B U42is more closely related to HCMV UL69 than to a27 in its
xpression kinetics. U73 transcripts did not accumulate
a
gnder conditions of inhibited protein synthesis, which is
onsistent with the presumption that as a gene involved
n DNA synthesis, it would not be expressed as an IE
ene (Fig. 6B). For U94, the results were equivocal due to
he low copy numbers (,1 transcript per cell) of U94
RNA extracted from control cells at 8 h p.i. (data not
hown). Therefore, unlike the other HHV-6 transcripts
xamined, the expression kinetics of U94 could not be
efinitively classified.
oding content of the HHV-6B(Z29) U94 mRNA
equence and its translation initiation environment
Figure 7A shows the open reading frames present in
he mRNA species deduced from the mRNA mapping
tudies. The mRNA sequence differs from most herpes-
irus mRNAs and mRNAs that encode efficiently ex-
ressed genes by the presence of several small AUG-
nitiated ORFs upstream from U94. When the sequences
urrounding the potential translation initiation codons
re compared with the Kozak consensus sequence for
fficient translation initiation (Kozak, 1989), two sites (G1
nd G2) at or near the 59 end of U94 do not appear to
ualify as efficient sites, and none of the others fully
atch the consensus (Fig. 7A). The combination of mul-
iple upstream AUG-initiated small ORFs and a subopti-
al translation environment for the expressed protein is
ommonly seen for genes that function near the begin-
ing of regulatory cascades or whose expression at high
evels might be deleterious to the cell (Kozak, 1991). Two
f the upstream AUG-initiated small ORFs are not
resent in HHV-6A, but they are replaced with two not
epresented in HHV-6B (not shown). Further, as de-
cribed earlier, a third downstream start codon only in
he HHV-6A U94 ORF has a well conserved Kozak con-
ensus sequence.
We compared the preference of codon use for trans-
ation initiation between HHV-6A and HHV-6B in vitro in a
oupled transcription-translation system. Major products
f approximately 54 and 56 kDa were present in reac-
ions programmed with plasmids encoding full-length
94 derived from HHV-6A(U1102) and HHV-6B(Z29) in
ddition to a low-passage clinical isolate of each variant
Fig. 7B, lanes 2–6). These protein mobilities correspond
o those predicted from G1 and G2 start codon use in Fig.
A. The largest product predicted to initiate from the G1
odon has an identical mobility to baculovirus-expressed
94 (data not shown). There was no evidence of a
ower-mobility product initiating from the third in-frame
tart codon in the reactions programmed with HHV-6A-
erived U94 (Fig. 7B, lanes 2–3).
To determine whether the smaller protein present in all
anes might be due to C-terminal proteolysis or prema-
ure translation termination, we evaluated the products ofcoupled in vitro transcription translation reaction pro-
rammed with a plasmid encoding a C-terminally trun-
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511HHV-6B U94 SEQUENCE AND EXPRESSIONcated U94. Truncated proteins of approximately 27 and
29 kDa were expressed, consistent with translation ini-
tiation from the G1 and G2 start codons (Fig. 7B, lane 7).
A second C-terminal mutant with a different deletion also
gave the predicted truncated products (data not shown).
Mutagenesis of the second start codon is required to
address the minor possibility of N-terminal proteolysis.
DISCUSSION
In this work, we studied sequence heterogeneity of
HHV-6 U94 genes and transcriptional regulation of
HHV-6B U94. We found (1) high intervariant and intravari-
ant sequence conservation, including 100% identity
among 13 HHV-6B isolates from three continents; (2) that
U94 transcripts are spliced; (3) that U94 transcripts are
expressed at very low levels during infection; and (4) that
the environment for translation initiation appears to have
been designed for inefficient translation. In addition to
the similarity of U94 with its parvovirus homologs, these
properties support the hypothesis that the U94 protein
has a role in gene regulation.
FIG. 7. Translation initiation environment and codon use of U94 mRNA
mRNA. The upper panel shows AUG-initiated open reading frames in
mapped. The location of a putative TATA box, the most abundant 59 end
context of the upstream and U94 potential initiation codons for ORFs A
translation initiation environments (Kozak, 1989). The scale coordinates
f HHV-6 U94. Coupled transcription-translation reactions programmed
rom HHV-6A (isolates U1102 and CO-1, lanes 2 and 3) and HHV-6B (i
runcated HHV-6B U94 (pH6Z-4204, lane 7) were incubated in the pres
as mixed with loading buffer, analyzed by SDS–PAGE, and detected by
he G1 and G2 codons are indicated with closed and open symbols,
esolution of the two products.The variant-specific classification of HHV-6 isolates as
HHV-6A or HHV-6B is based on their differential ability to
a
pgrow in some cell types, patterns of reactivity with panels
of monoclonal antibodies, and epidemiology (Ablashi et
al., 1993). These properties are rooted in the genetic
divergence revealed by heterogeneity of restriction en-
donuclease restriction patterns and nucleotide se-
quences. It was relevant to examine geographically dis-
tinct isolates of each variant for genetic heterogeneity in
U94, a gene unique to HHV-6A and HHV-6B among
herpesviruses. There was high conservation at both the
nucleotide and amino acid levels. Based on U94 amino
acid sequences, the isolates studied segregated into
variant-specific groups consistent with previous classifi-
cations based on markers such as restriction endonu-
clease profiles, reactivity with monoclonal antibodies,
and cell tropism (Pellett et al., 1990; Ablashi et al., 1991;
ruksananonda et al., 1992). The high degree of genetic
onservation of U94 suggests that it provides a critical
unction in the HHV-6 life-cycle nearly intolerant of se-
uence variation. The existence of easily distinguished
ariant versions of the U94 gene, however, further sup-
orts the consideration of HHV-6A and HHV-6B as sep-
ding capacity and translation initiation environment of the spliced U94
f the three translational reading frames of the longest mRNA species
e splice site are indicated. The lower panel shows the initiation codon
h G (G is U94) relative to the Kozak consensus sequence for efficient
ative to the 59 end of the longest cDNA species. (B) In vitro expression
t added DNA (lane 1) or with plasmids encoding full-length U94 derived
Z29 and R-24, lanes 4 and 5 and pH6Z-4201, lane 5) or C-terminally
f 35S-methionine. One tenth of the labeled protein from each reaction
raphy. Expected bands corresponding to protein products derived from
tively. Lane 7 was exposed for a shorter time period to enable better. (A) Co
each o
, and th
thoug
are rel
withou
solates
ence o
fluorograte entities that have followed divergent evolutionary
athways.
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512 RAPP ET AL.Transcription mapping demonstrated that U94 tran-
scripts are spliced during an HHV-6B infection. The U94
splicing signals are conserved between HHV-6A and
HHV-6B. Splicing of herpesvirus transcripts is not com-
mon, occurring most often in transcripts encoding regu-
latory proteins. Herpesvirus mRNA splicing is a potential
target for transcriptional regulation by viral gene prod-
ucts or by infection-induced modification of the host
cell’s splicing mechanism. It will be interesting to deter-
mine whether there are variant-specific differences in
U94 transcript splicing and expression kinetics.
To identify promoter/regulatory elements that might
control the expression of U94, the 59 end of its transcript
was mapped. The 59 terminus is at a distance from the
ORF because of a 2.6-kb intron present in the 59 leader
sequence. The most abundant 59 terminus mapped 25
nucleotides downstream from a TATACA sequence that
potentially encodes a TATA box. The sequence upstream
from the TATA sequence contains potential binding sites
or several transcription factors, including SP1, PEA3,
nd AP-2. Further experiments will be needed to confirm
his 59 region as the true U94 promoter.
At most time points after infection, U94 transcripts
ere the least abundant of the five genes studied. A
egative regulatory mechanism of U94 expression may
e used to maintain the low abundance of U94 mRNA.
he low transcript levels, coupled with the apparently
nefficient translation initiation environment, are consis-
ent with our inability to detect U94 protein. Our results
uggest that the U94 protein may be required in only
mall amounts during infection.
Mirandola et al. (1998) published a study of HHV-6
ranscription. Our results differ from theirs in several
ays. Of the genes studied in common, Mirandola et al.
ound that U42, U73, U89, and U94 are expressed as IE
enes, in comparison with our observations that U90
previously identified as U89) is expressed as an IE gene,
42 and U73 expression is dependent on de novo pro-
ein synthesis, and U94 was expressed at levels too low
o allow unambiguous determination of its kinetic class.
he differences in the results may have resulted from the
se of qualitative PCR versus quantitative PCR. In our
ork, levels of expression were measured by QC RT-
CR, with the results being expressed as copies per cell.
n the study by Mirandola et al. (1998), results were
btained by visual inspection of ethidium bromide-
tained gels. Perhaps more importantly, Mirandola et al.
1998) used 35 cycles of PCR to amplify their RT prod-
cts; we used the fewest number of cycles that produced
eadily detectable PCR products to remain in the expo-
ential phase of amplification. It is possible that small
umbers of “leaky” transcripts were amplified to the point
f visibility by the end of 35 amplification cycles. For
etter or worse, our results do not require the develop-
ent of any new paradigms for herpesvirus gene regu-
ation; in our hands, the DNA replication (U73) and struc-ural (U11) genes studied required de novo protein syn-
hesis for their expression, as do such genes in other
erpesviruses. U42, which is homologous to HCMV U69
nd the HSV-1 a27 gene, was not expressed in the
absence of de novo protein synthesis; this behavior is
similar to its more closely related HCMV counterpart
than to its more distantly related HSV homolog.
The U94 transcript is spliced and expressed at low
levels and contains a 59 mRNA upstream environment
that is likely to result in inefficient U94 translation. This
indicates that U94 expression is tightly regulated. Nu-
merous questions surround the function of U94, which is
a homolog of the parvovirus ns1 (rep) protein, a protein
with well defined transcriptional regulatory properties.
Several promoters can be regulated by both RepAAV-2 and
94, indicating that these proteins share at least some
unctional properties. These proteins have numerous
imilarities at the amino acid level in regions required by
epAAV-2 for NTP binding, helicase, and endonuclease
activity (Walker et al., 1997a, 1997b; Davis et al., 1999).
This suggests that U94 may have domains required for
DNA binding and helicase activity. Such activities are
likely to play a role in its regulatory function and also
suggest possible roles in DNA replication and perhaps
rare occurrences of HHV-6 genomic integration (Daibata
et al., 1998; Morris et al., 1999). The lack of a U94
homolog in the otherwise closely related HHV-7 indi-
cates U94 may have a significant role in HHV-6 patho-
genesis.
MATERIALS AND METHODS
Viruses and cell culture
Fifteen low-passage HHV-6 clinical isolates from four
distinct geographic regions were used for U94 hetero-
geneity analysis. The commonly studied isolates, HHV-
6A(U1102) and HHV-6B(Z29), originated in Africa (Uganda
and Zaire, respectively) (Downing et al., 1987; Lopez et
al., 1988). HHV-6A isolates CO-1, CO-7, and CO-8 were
from Cologne, Germany (Ablashi et al., 1991), and were
gifts from Dr. Bala Chandran. HHV-6B isolates R-4, R-10,
R-15, and R-24 were obtained in Rochester, NY, and were
gifts from Dr. Caroline Hall (Pruksananonda et al., 1992).
HHV-6B isolates J1-C, J1-E, J1-H, and J1-L (Pellett et al.,
1990) were obtained from Japanese exanthem subitum
patients in the vicinity of Osaka, Japan, and were gifts
from Dr. Koichi Yamanishi. HHV-6B isolates J2-G, J2-H,
J2-I, and J2-J were obtained from Japanese exanthem
subitum patients in northern Japan and were gifts from
Dr. Kazuo Yanagi. Viruses were cultured as previously
described (Black et al., 1989).
For mRNA studies, HHV-6B(Z29) was propagated in
human umbilical cord blood lymphocytes (CBLs) as
previously described (Black et al., 1989) or in Molt-3
cells that were cultured in the same medium as that
used for CBLs except no phytohemagglutinin or inter-
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513HHV-6B U94 SEQUENCE AND EXPRESSIONleukin-2 was used. Cells were infected with a cell-free
virus stock at a multiplicity of infection (m.o.i.) of 0.15.
After 2 h, inoculation medium was replaced with fresh
medium. Typical infectivities at 72 h p.i. were 23–33%
for Molt-3 cells and 12–17% for CBLs as determined by
immunofluorescence with a monoclonal antibody
against HHV-6 p41 (Advanced Biotechnologies, Inc.,
Columbia, MD).
Plasmid construction and sequence analysis
For the study of U94 genetic heterogeneity among
clinical isolates, HHV-6 DNA was prepared as previously
described (Straus et al., 1981; Kadakia et al., 1996;
Lindquester et al., 1996). A 1735-bp product containing
the 1470-bp U94 ORF was amplified using primers
U94PCR5 and U94PCR3 (Table 1). Proofreading poly-
merases were used to reduce possible errors arising
during PCR. To decrease contamination risks, PCR reac-
tions were prepared in a biological safety cabinet that
had been UV irradiated for several hours before use,
located on a different floor from the template preparation
area.
Amplified DNA fragments were blunt-ended by Pfu
DNA polymerase (Stratagene, La Jolla, CA) treatment
and ligated to SrfI-digested pCR-Script according to
the manufacturer’s recommendations (Stratagene) and
then cycle sequenced using fluorescent dye termina-
tors (Applied Biosystems, Foster City, CA). The se-
quence of both strands was determined with an over-
all 4-fold redundancy. Sequences were analyzed using
GCG Version 9.0 (GCG, Madison, WI). Unique nucleo-
tide sequence changes were confirmed by resequenc-
ing the original amplified material as well as by se-
quencing a second clone. The integrity of this ap-
proach was verified by independently reproducing the
previously determined U94 nucleotide sequences of
HHV-6A(U1102) (Thomson et al., 1991) and HHV-
B(Z29) (Dominguez et al., 1999).
For use in the in vitro translation analysis, pH6Z-4201
nd pH6Z-4204 were constructed as follows. pH6Z-204
ontaining the HHV-6B(Z29) HindIII-C fragment
Lindquester et al., 1996) was digested with XbaI and
pnI. The XbaI–KpnI fragment was inserted between the
baI and KpnI site of pBluescript II KS(1) (Stratagene) to
onstruct pH6Z-4201. pH6Z-4201 was digested with MluI,
reated with T4 DNA polymerase in the presence of all
our dNTPs, and re-ligated to construct pH6Z-4204. This
esults in the generation of a frameshift mutation at
mino acid 246 and an in-frame termination codon at
mino acid 253.
NA extraction
Total RNA was extracted from 107 viable cells (as
etermined by trypan blue exclusion) with guanidinium
hiocyanate–phenol (RNAzol B; CINNA/BIOTECX Labora-ories International Inc., Friendswood, TX). mRNA was
urified from total RNA on an oligo(dT) matrix (QuickPrep
icro mRNA Purification Kit; Pharmacia, Piscataway, NJ)
nd then stored at 270°C.
ranscript mapping
The 39 end of the U94 transcript was determined by
LM-RACE (Liu and Gorovsky, 1993). Briefly, 1 mg of
mRNA extracted from CBLs 7 d p.i. was DNase treated
(RQ-1; Promega, Madison, WI) for 50 min at 37°C. DNase
was inactivated at 90°C for 5 min. Phosphorylated SK
oligonucleotide (Stratagene) was ligated to the RNA
sample with 100 U of T4 RNA ligase (New England
BioLabs, Inc., Beverly, MA). First-strand cDNA synthesis
was performed using 2 pmol of the reverse complement
of SK oligomer (RCOFSK) and 200 U of reverse transcrip-
tase (RT) (SuperScript II; GIBCO BRL, Gaithersburg, MD).
The initial round of PCR was performed with 1/50th of the
RT reaction as template, Taq DNA polymerase (Perkin
Elmer, Norwalk, CT), and primers U94RTP5 (Table 1) and
RCOFSK. Cycling conditions were 93°C for 1 min, 48°C
for 1 min, and then 72°C for 2 min, for a total of 35 cycles.
For the second round of PCR, 1/100th of the primary PCR
was used as template with U94mut (Table 1) and
RCOFSK as primers. Cycling conditions were identical to
the initial round of PCR except only 30 cycles were used.
Bands were eluted from a 2% agarose gel, cloned into
pBluescript KS(2), and then sequenced as described
earlier.
The 59 end of the U94 transcript was mapped by
oligo-capping (Maruyama and Sugano, 1994). One micro-
gram of mRNA was DNase treated as described for 39
end mapping, incubated with 1 U of thermolabile phos-
phatase (HK phosphatase; Epicentre, Madison, WI),
heat-inactivated, and then extracted with phenol and
chloroform. After centrifugally dialyzing twice, the RNA
sample was treated with 5 U of tobacco acid pyrophos-
phatase (Epicentre), extracted with phenol and chloro-
form, and then dialyzed centrifugally. Gel-purified RNA
oligonucleotides transcribed from EcoRI-linearized
pBluescript KS(2) (MEGAscript; Ambion, Austin, TX)
were ligated to the RNA sample with 100 U of T4 RNA
ligase (New England BioLabs) and then incubated with
200 U of RT and 2.5 mM random hexamers (GIBCO BRL).
The initial round of PCR was performed with one fifth of
the RT reaction as template and with primers 081 (Table
1) and SK. Thermal cycling conditions were 93°C for 1
min, 50°C for 1 min, and then 72°C for 1 min, for a total
of 30 cycles. Second-round PCR was performed with one
fifth of the initial round PCR products as template and
with primers 080 (Table 1) and SK. Thermal cycling con-
ditions were identical to the initial round of PCR. Am-
plimers were purified, cloned, and sequenced as de-
scribed earlier.
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514 RAPP ET AL.Quantitative competitive RT-PCR (QC RT-PCR)
Templates for the production of competitor RNAs were
prepared by the introduction of restriction site mutations
into U11, U42, U73, U90, and U94 genes by recombinant
PCR (Higuchi et al., 1988). The resulting PCR products
ontaining the restriction site mutation (listed in Table 1)
ere cloned into pBluescript KS(2) by T-vector ligation
Marchuk et al., 1991). Linearized competitor plasmids
ere in vitro transcribed at 25°C (MEGAscript), yielding
predominantly full-length transcripts as determined by
agarose gel electrophoresis of samples treated with
formaldehyde and ethidium bromide (Liu and Chou,
1990).
Quantification of mRNA was done in two steps (Ra-
makrishnan et al., 1994). The first used a 10-fold dilu-
tion series of the competitor template in the presence
of a constant amount of infected-cell mRNA and was
intended to provide an approximation of the abun-
dance of an RNA; the second used a 2-fold dilution
series centered around the approximate value to ob-
tain a more precise value. Briefly, competitor RNAs
were suspended in 7 mg/ml yeast tRNA (Sigma Chem-
ical Co., St. Louis, MO). Infected-cell and competitor
RNA dilutions were then treated with DNaseI for 1 h at
37°C and 6 min at 90°C and then immediately placed
on ice. RT reactions were performed on the products
of the DNaseI reactions with random hexamer primers
(GeneAmp RNA PCR kit; Perkin–Elmer Cetus, Norwalk,
CT). PCRs were performed according to the kit proto-
col with the addition of 1 ml of [a-32P]dCTP (3000
Ci/mmol) and primer sets designated by the RTP5 and
RTP3 suffixes in Table 1. Thermal cycling parameters
were 2 min at 95°C for 1 cycle, 1 min at 95°C, and 1
min at 60°C for 20–27 cycles and then 7 min at 60°C
for 1 cycle. The fewest number of cycles that produced
readily detectable PCR products were used to remain
in the exponential phase of amplification and to avoid
heteroduplex formation. Aliquots of 15 ml of each co-
mplified RT-PCR were removed and digested with the
ppropriate restriction endonuclease (Table 1) over-
ight at 37°C to allow discrimination of infected-cell
T-PCR products from mutant competitor RT-PCR
roducts. Products were then separated by electro-
horesis on an 8% polyacrylamide gel and quantified
Betascope 603 Blot Analyzer, Betagen, Mountain
iew, CA). Controls consisted of an RT-PCR in which
T was absent from the reaction and an RT-PCR with
ock-infected cell mRNA as template. Equivalence
oints were computed as described previously (Piatak
t al., 1993), taking into account the dCTP content of
he amplimers.
rotein synthesis inhibitor treatmentsVarious concentrations of the protein synthesis inhib-
tors emetine, cycloheximide, or anisomycin (Mackemnd Roizman, 1981) were tested to determine optimal
onditions for protein synthesis inhibition in HHV-
B(Z29)-infected Molt-3 cells. Because treatment with 50
mg/ml emetine had the least residual protein synthesis
(8%) and the least effect on cell viability, these conditions
were used in subsequent experiments.
In vitro translation
U94 protein was expressed in vitro in coupled tran-
scription-translation reactions (Promega) programmed
with 2 mg of plasmid DNA. U94 from HHV-6A isolates
1102 and CO-1 and HHV-6B isolates Z29 and R-24 was
xpressed from plasmids used for the genetic heteroge-
eity study. 35S-Labeled in vitro-translated products were
mixed with an equal volume of loading buffer containing
2% SDS and 1.8 M 2-mercaptoethanol and separated on
a 10% SDS–polyacrylamide gel. Gels were visualized by
fluorography as described previously (Inoue et al., 1994).
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